NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KPTI shares have decreased by 7.8% and is now trading at $19.58. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karyopharm Therapeutics.

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Karyopharm Therapeutics.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its quarterly earnings results on Thursday, February, 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.10. The company earned $18.10 million during the quarter, compared to analyst estimates of $16.48 million. Karyopharm Therapeutics had a negative return on equity of 254.74% and a negative net margin of 488.08%. View Karyopharm Therapeutics' earnings history.

8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $25.00 to $43.00. On average, they expect Karyopharm Therapeutics' stock price to reach $30.71 in the next year. This suggests a possible upside of 56.9% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics.

Media coverage about KPTI stock has trended very positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutKaryopharm Therapeutics.

Karyopharm Therapeutics saw a increase in short interest in the month of February. As of February 14th, there was short interest totaling 12,930,000 shares, an increase of 34.4% from the January 30th total of 9,620,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 11.1 days. Currently, 24.2% of the shares of the company are sold short. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN) and GW Pharmaceuticals PLC- (GWPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Amarin (AMRN), Exelixis (EXEL), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Palo Alto Investors LP (7.32%), State Street Corp (5.14%), Delphi Management Partners VIII L.L.C. (3.60%), Candriam Luxembourg S.C.A. (1.35%), Geode Capital Management LLC (1.32%) and FMR LLC (1.01%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View institutional ownership trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, J. Goldman & Co LP, Palo Alto Investors LP, Candriam Luxembourg S.C.A., Schonfeld Strategic Advisors LLC, UBS Group AG, and FMR LLC. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, and Sharon Shacham. View insider buying and selling activity for Karyopharm Therapeutics.

KPTI stock was acquired by a variety of institutional investors in the last quarter, including Delphi Management Partners VIII L.L.C., Parkman Healthcare Partners LLC, Fairmount Funds Management LLC, Marshall Wace LLP, EAM Investors LLC, Renaissance Technologies LLC, California Public Employees Retirement System, and EAM Global Investors LLC. View insider buying and selling activity for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $19.58.

Karyopharm Therapeutics has a market capitalization of $1.28 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe. View additional information about Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]